New ECCO dietary therapy guidelines for IBD clarify the role of enteral nutrition, Mediterranean diet, supplements, and RD ...

The American Gastroenterological Association has updated guidance for the treatment of ulcerative colitis to recommend using higher efficacy drugs in earlier stages of treatment, Medscape Medical News ...

An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...

Aminosalicylate (5-ASA) therapy is often the first treatment option for patients presenting with mild to moderate ulcerative colitis (UC). Symptom improvements can be observed within 2 to 4 weeks ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

Please provide your email address to receive an email when new articles are posted on . A greater proportion of patients in the PRA023 group achieved clinical remission at 12 weeks vs. placebo (26.5% ...

A 52-week phase 3 clinical trial of Skyrizi, or risankizumab — a drug initially approved to treat Crohn’s disease, psoriatic arthritis and psoriasis — was shown to also achieve clinical remission in ...

Nearly 70% of adolescents and young adults stop taking oral 5-aminosalicylic acid (5-ASA) maintenance therapy within 12 months of ulcerative colitis (UC) diagnosis, new research from the United ...